Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931.

Abstract	[This corrects the article DOI: 10.3389/fimmu.2018.01355.].
Authors	M Fevzi Ozkaynak, Andrew L Gilman, Wendy B London, Arlene Naranjo, Mitchell B Diccianni, Sheena C Tenney, Malcolm Smith, Karen S Messer, Robert Seeger, C Patrick Reynolds, L Mary Smith, Barry L Shulkin, Marguerite Parisi, John M Maris, Julie R Park, Paul M Sondel, Alice L Yu
Journal	Frontiers in immunology (Front Immunol) Vol. 9 Pg. 1641 ( 2018) ISSN: 1664-3224 [Print] Switzerland
PMID	30046297 (Publication Type: Journal Article, Published Erratum)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!